Pharmaceutical Technology3 天
Risk adjusted net present value: What is the current valuation of Philogen’s Fibromun?
Fibromun is a fusion protein commercialized by Philogen, with a leading Phase III program in Soft Tissue Sarcoma.
Pharmaceutical Technology5 天
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Volrustomig?
Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Malignant Pleural Mesothelioma.